Brief: OSE Immunotherapeutics Presents Preclinical Data On Lymphoblastic Leukemia Treatment OSE-127

Ose Immunotherapeutics SA

13/12/2021 07:07

Dec 13 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS PRESENTS FIRST PRECLINICAL EFFICACY
DATA
ON ANTI-IL-7 RECEPTOR ANTAGONIST OSE-127 IN ACUTE LYMPHOBLASTIC
LEUKEMIA
    * RESEARCH TEAMS DEMONSTRATED THAT USING OSE-127 TO TARGET
IL-7R
IS AN EFFICIENT APPROACH FOR BCP-ALL IMMUNOTHERAPY AND MAY BE
PARTICULARLY BENEFICIAL FOR PATIENTS WITH HIGH IL-7R-EXPRESSION
AND/OR RELAPSED/REFRACTORY DISEASE AFTER ESCAPE TO CD19 ANTIGEN
THERAPY
    * OSE-127/S95011 IS BEING DEVELOPED IN PARTNERSHIP WITH
SERVIER AS
PART OF A COLLABORATION AGREEMENT
    * PRODUCT HAD ALREADY DEMONSTRATED PHASE 1 POSITIVE RESULTS
WITH A
GOOD SAFETY AND TOLERABILITY PROFILE SHOWING NO SIGNS OF
LYMPHOPENIA, CYTOKINE RELEASE SYNDROME, OR T-CELL COMPARTMENT
ALTERATIONS

Source text for Eikon:  ID:nGNX774Xbs 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))